Investors seeking relief from the stock market turbulence at the start of 2025 should take a close look at Vertex Pharmaceuticals (NASDAQ: VRTX). Compared to the S&P 500 index, which is down about ...

Vertex Pharmaceuticals (VRTX ... review some of the factors that might affect the near-term performance of the stock. Shares of this drugmaker have returned -3.7% over the past month versus ...

Vertex Pharmaceuticals (NASDAQ:VRTX) is set to release its earnings on Monday, May 5, 2025. For those trading based on events, analyzing historical stock behavior around earnings announcements can ...

Vertex Pharmaceuticals (NASDAQ: VRTX) had a fine Tuesday on the stock exchange. The biotech's shares closed the day nearly 3% higher in price, on the back of two positive mentions by analysts ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $475.49, marking a -1.41% move from the previous day. The stock outperformed the S&P 500, which registered a daily loss of 3.46%.

Shares of Vertex Pharmaceuticals Inc. VRTX rose 2.10% to $482.30 Wednesday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 9.52% ...

Shares of Vertex Pharmaceuticals Inc. VRTX slid 2.09% to $498.86 Thursday, on what proved to be an all-around great trading session for the stock market, with the S&P 500 Index SPX rising 0.63% to ...

Will these developments be enough to sustain the rally? Let's discuss whether Vertex Pharmaceuticals stock is a buy now. The past year has been transformative for Vertex, marked by the launch of ...